Skip to main content
. Author manuscript; available in PMC: 2017 Feb 20.
Published in final edited form as: Clin Cancer Res. 2011 Feb 8;17(4):888–895. doi: 10.1158/1078-0432.CCR-10-1706

Figure 4.

Figure 4

Progression-free and overall survival following SVV-001 administration. Kaplan–Meier survival plots are presented, by disease type. All dose cohorts for mixed neuroendocrine are combined. All study subjects are included. PFS, progression-free survival; OS, overall survival.